ファモチジンを含むキトザン混合フィブロインナノ粒子は,胃潰瘍の改善に優れた有効性を示しています
Walaa A El-Dakroury1, Gihan F Asaad2, Marwa E Shabana3
1Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Badr University in Cairo (BUC), Badr City, Cairo, 11829, Egypt.
International journal of biological macromolecules
|September 6, 2025
まとめ
シルクフィブロイン・キトーサンナノ粒子は 胃潰瘍に対するファモチジンの投与を促進する. これらの新しいナノ粒子は 薬の保持を改善し 重要な胃保護効果を示し 潰瘍の治癒を促進します
科学分野:
- バイオマテリアル科学
- ナノテクノロジー
- 薬理学について
背景:
- ファモチジン (FMD) の経口生物利用度と半減期は限られており,効果的な胃潰瘍治療を妨げています.
- FMDの治療効果と粘膜保持を改善するために,新しいナノキャリアシステムが必要です.
- シルク繊維キトーサンナノ粒子 (FBN-CS-NP) は,バイオコンパティブルで粘着性のあるプラットフォームとして有望です.
研究 の 目的:
- 強化されたファモチジン (FMD) 配給のためのシルク繊維素-キトーサンナノ粒子 (FBN-CS-NP) の開発と特徴付け.
- FMDに感染したFBN-CS-NPの in vitro 薬の放出と in vivo 胃保護効果を評価する.
- 薬物の投与と粘膜の治癒のための二重機能のプラットフォームとしてのFBN-CS-NPの可能性を調査する.
主な方法:
- 繊維素とキトサンの間の静電相互作用によるナノ粒子製剤.
- 粒子の大きさ,ゼータポテンシャル,捕獲効率,形状 (TEM) の特徴.
- 薬の放出試験と胃潰瘍のラットモデルの in vivo 評価
主要な成果:
- 最適化されたFBN-CS-NPは94.4nmの粒子サイズ,+65.3mVのゼータポテンシャル,および91.5%の捕獲効率を示した.
- 24時間以上の FMD の継続的な in vitro 放出が観察されました.
- 活体試験では,抗酸化防御,eNOS発現,H+/ K+ ATPaseおよびcAMPレベルが著しく改善されたことが示されました.
結論:
- FBN- CS- NPはファモチジンの有効なナノキャリアであり,その薬理 Profil farmakokinetik jo kagunoan terapeutic.
- シルク繊維素-キトーサンマトリックス自体には固有の胃保護性があります.
- FMD-FBN-CS-NPは 胃潰瘍の治療のための 新しく有望な治療戦略です
さらに関連する動画
関連する概念動画
01:26Peptic Ulcer Disease IV: Management
144
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
144
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
525
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
525
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
680
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
680
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
595
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
595
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
568
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
568
01:30Peptic Ulcer Disease I: Introduction
282
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
282